Needham Maintains Buy on RxSight, Raises Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
Needham analyst David Saxon has reaffirmed a Buy rating on RxSight (NASDAQ:RXST) and increased the price target from $35 to $41.
January 08, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst David Saxon maintains a Buy rating on RxSight and raises the price target from $35 to $41, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100